MetLife’s new deferred payment solution puts product design in focus

MetLife (MET) recently introduced the Non-Qualified Assignment Flex Agreement, or NQA-FA, a deferred payment solution that gives attorneys and brokers more control over the timing and structure of non-physical injury settlements.

The NQA-FA uses a funding agreement rather than an annuity and supports features such as deferred start dates, lump sums and customized payment schedules, potentially broadening how MetLife stock investors view the company’s role in the legal settlements market.

At a share price of $87.40, MetLife has delivered a 27.41% 90 day share price return and a 75.57% 3 year total shareholder return. This suggests momentum has been building around recent product launches and investor expectations.

If this kind of product expansion has your attention, it may be a good moment to look beyond insurance and check out 20 top founder-led companies

With MetLife stock up 27.41% over 90 days and 75.57% on a 3 year total return, yet trading about 5% below the average analyst target and at a reported intrinsic discount of 47.32%, is there still an opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 5.8% Undervalued

MetLife stock closed at $87.40, against a widely followed fair value narrative of $92.80 that is built on detailed revenue, margin and earnings assumptions.

Strong, sustained premium and sales growth in high-potential international markets (Asia, Latin America, EMEA) positions MetLife to capitalize on growing middle-class wealth and increased insurance penetration, supporting long-term revenue and top-line growth.

Ongoing investment in digital transformation (AI-driven underwriting, process automation, embedded insurance partnerships, and tech-enabled distribution) is intended to help MetLife reduce acquisition and operating costs, improve customer engagement and retention, and, over time, increase net margins.

Want to see how MetLife’s international expansion, fee based focus and margin uplift assumptions connect to that value gap? The full narrative sets out the revenue path, earnings bridge and re rating logic that sit behind the $92.80 figure.

Result: Fair Value of $92.80 (UNDERVALUED)

However, MetLife stock is still tied to interest rate sensitivity and commercial mortgage credit risk, either of which could quickly challenge the current fair value story.

Another view on MetLife’s valuation

While the most popular MetLife narrative leans on discounted cash flows and points to the stock trading at a 47.3% discount to an estimated fair value of $165.91, the current 16.4x P/E looks fuller when set against the US Insurance industry at 11.2x and a fair ratio of 13.3x. Is the market cheaply mispricing future cash flows, or is the higher earnings multiple already doing some of that work?

To unpack what this P/E gap might mean for upside potential or downside risk, and how it compares to both peers and that fair ratio the market could move toward, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and concern around MetLife, it makes sense to move quickly and review the underlying data yourself. To weigh up both the potential rewards and the risks that investors are watching, start by reviewing the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond MetLife stock?

If MetLife has sharpened your focus on quality opportunities, do not stop here. Use the Simply Wall Street Screener to surface more targeted stock ideas today.

• Target income potential by reviewing companies that stand out as 9 dividend fortresses for investors who want yield with a clear financial story behind it.
• Hunt for value by scanning screener containing 20 high quality undiscovered gems that the broader market may not be paying close attention to yet.
• Prioritise resilience by assessing 68 resilient stocks with low risk scores that may suit investors who want steadier return profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.